{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:21Z","timestamp":1793146401364,"version":"4.5.0"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti\u2010apoptotic protein MCL1. In an investigator\u2010sponsored, open\u2010label, phase Ib study (NCT03955783), adult patients with relapsed or refractory acute myeloid leukemia (R\/R AML) were enrolled. After the dose\u2010escalation phase, SEL 80\u2009mg po weekly plus VEN 400\u2009mg\/day following ramp\u2010up was deemed the recommended phase II dose. Responses were assessed with IWG2003 and ELN 2022 criteria. Nineteen patients with R\/R AML were enrolled. Median age at enrollment was 67.2 (range, 21.1\u201383.8) years. Overall, patients received median of 3 (range, 1\u20135) prior lines of therapy. The most common grade 3\u20135 treatment emergent adverse events (TEAE) were anemia (39%), neutropenia (33%), febrile neutropenia (28%), and thrombocytopenia (28%). Overall, the response rate with SEL\u2010VEN was 21%. Two (11%) patients, one with prior allo\u2010HSCT and one with prior VEN and both treated with SEL 80\u2009mg\/week, experienced complete remissions, with duration of response of 7 and 9.1\u2009months, respectively. After a median follow up of 3.0 (range, 0.6\u201315.4) months, median event\u2010free survival was 2.4 (95% CI: 1.9\u201312.1) months and median overall survival was 6.4 (95% CI: 2.5\u201312.1) months. In conclusion, SEL\u2010VEN was feasible and active in a heavily pretreated AML cohort, with no new toxicity signal, but survival outcomes remained poor. The second\u2010generation XPO1\u2010inhibitor eltanexor, combined with VEN may further improve outcomes in VEN resistant AML in an ongoing study (NCT06399640).<\/jats:p>","DOI":"10.1002\/ajh.70266","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:01:32Z","timestamp":1773032492000},"page":"1019-1024","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia"],"prefix":"10.1002","volume":"101","author":[{"given":"Somedeb","family":"Ball","sequence":"first","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center  Nashville Tennessee USA"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben K.","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplant University Hospitals Seidman Cancer Center  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Stopczynski","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Fedorov","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center  Nashville Tennessee USA"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center  Nashville Tennessee USA"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R.","family":"Mohan","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center  Nashville Tennessee USA"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Ayers","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2966-4877","authenticated-orcid":false,"given":"Michael T.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center  Nashville Tennessee USA"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine Vanderbilt University School of Medicine  Nashville Tennessee USA"},{"name":"Tennessee Oncology  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5504","authenticated-orcid":false,"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center  Nashville Tennessee USA"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine Vanderbilt University School of Medicine  Nashville Tennessee USA"},{"name":"Program in Cancer Biology, Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01143-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280631"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.03.001"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000359"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02570-1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0424"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.194"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750158"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.252569"},{"key":"e_1_2_9_15_1","unstructured":"ASH Clinical News \u201cFDA Places Trials of MCL\u20101 Inhibitor on Clinical Hold \u201d2019."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100672"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S429402"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17274"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231208608"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02328-1"},{"issue":"8","key":"e_1_2_9_21_1","first-page":"772","article-title":"The Clinical Safety and Efficacy of Selinexor Combined With Venetoclax and Azactitidine Induction Therapy in Relapsed and Refractory Acute Myeloid Leukemia","volume":"45","author":"Liu L. N.","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:37:38Z","timestamp":1776242258000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/ajh.70266"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70266","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"2026-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}